Pfizer to Provide U.S. Government with an Additional 10 Million Treatment Courses of its Oral Therapy to Help Combat COVID-19 Pharmaceutical Investing
Abbott's Proclaim XR Spinal Cord Stimulation System Now Offers Expanded MRI Compatibility in U.S. Pharmaceutical Investing
AbbVie Announces U.S. FDA Granted Breakthrough Therapy Designation to Telisotuzumab Vedotin for Previously Treated Non-Small Cell Lung Cancer Pharmaceutical Investing
Vaccinex Reports Phase Ib KEYNOTE B84 Combination Study of Keytruda® and Pepinemab in Patients with Advanced, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Passes Planned Interim Safety Analysis Life Science Investing
NEW SURVEY FROM BAUSCH + LOMB AND GLAUCOMA RESEARCH FOUNDATION REVEALS EMOTIONAL AND SOCIAL IMPACT OF HYPEREMIA ON GLAUCOMA PATIENTS Pharmaceutical Investing
Bristol Myers Squibb to Present at J.P. Morgan's 40th Annual Healthcare Conference Pharmaceutical Investing
Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization of COVID-19 Vaccine Booster for Individuals 12 Years of Age and Older Pharmaceutical Investing
Seegnal Inc. Establishes Strategic Commercialization Team and Appoints Arx as Investor Relations Advisor
